gradual process characterized by morphological changes such as the appearance of the cytoskeleton protein smooth muscle ␣-actin (␣-SMA), the loss of vitamin A droplets, and an increase of rough endoplasmic reticulum. Metabolically, an increase in cellular proliferation and in the synthesis of type I and III collagens, fibronectin, and tissue inhibitor of matrix metalloproteinases occurs following activation (20 -22) . Understanding the transcriptional mechanisms that drive this phenotype switch is indispensable to the development of targeted antifibrotic therapies.
Snail1 belongs to the Snail gene family, zinc-finger transcription factors essential for mesoderm and neural crest formation, cell fate and survival decisions, and left-right identity (29) . They act as transcriptional repressors by binding to E-box sequences, the consensus of the core binding site of basic helix-loop-helix transcription factors. The function that Snail genes are best known for is the induction of epithelial-mesenchymal transition (EMT) during embryonic development and tumor progression, but they can also regulate cell adhesion and migration and confer survival properties (3, 12) .
In vertebrates, there is evidence for the regulation of Snail1 at the transcriptional level by the activity of several signaling pathways, including ERK2, NF-B, and phosphatidylinositol 3-kinase (PI 3-kinase) (1, 2, 33) , all of which have been involved in the activation process of HSC (43) . Furthermore, several studies have reported Snail1 overexpression in pathological conditions associated with the deposition of fibrotic tissue, such as the EMT of mesothelial cells (47) in patients subjected to prolonged peritoneal dialysis, and in kidney cells (37) following unilateral ureteral obstruction in mice. These pathological processes can be induced by transforming growth factor (TGF)-␤, a potent Snail1 activator and profibrogenic stimulus for HSC. Recent studies have shown that Snail1 activation is sufficient to trigger kidney fibrosis in transgenic mice, and it is activated in patients with renal fibrosis (5) . In vitro experiments demonstrated that Snail1 expression can be induced in human fibroblasts through serum addition (19) . Moreover, using an in vivo wound-healing assay in mice, Snail1 immunoreactivity localized specifically in activated migrating fibroblasts (19) . These studies prompted us to hypothesize a role for Snail1 in the HSC activation process. Therefore, we analyzed the expression and functional relevance of Snail1 transcription factor in HSC in an experimental model of liver injury.
MATERIALS AND METHODS

Animal Model of Liver Injury
All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Padova. Mice were kept in standard laboratory conditions with 12:12-h light-dark cycles and free access to chow and water at all stages of the experimental model.
Chronic. Carbon tetrachloride (CCl 4, 0.25 l/g body wt in a 1:1 ratio with olive oil; Sigma) or thioacetamide (TAA, 200 mg/kg diluted in distilled water; Sigma) were administered intraperitoneally two times weekly for 8 wk to male CD1 mice. Liver were harvested 72 h after the last injection. Liver specimens were either snap-frozen for protein and RNA extraction, fixed in 10% formalin, or embedded in optimum-cutting temperature mounting medium.
Acute. After overnight fast, mice were injected intraperitoneally with 1 l/g body wt sterile CCl 4 in a 1:3 ratio with olive oil. Livers were harvested 72 h after the injection and processed for HSC isolation.
Control mice received only vehicle.
Cell Isolation, Purification, and Culture
Mouse HSC were isolated from normal livers or following CCl4 acute injury as described previously (7) . Briefly, aseptically removed livers were finely minced, digested with 0.5% wt/vol pronase E (Merck), 0.05% wt/vol type IV collagenase (Sigma), and 10 g/ml DNase I from bovine pancreas (Calbiochem), then filtered through a 100-m wire mesh and washed three times in HBSS (GIBCO). Cells were centrifuged through a two-step Percoll (Amersham Biosciences) 50% and 35% (vol/vol) gradient. HSC were collected, washed two times in HBSS, and then cultured for 20 h ("quiescent HSC" or "in vivo activated HSC") or for 8 -10 days ("culture-activated HSC") in Dulbecco's modified Eagle's medium, containing 16% heat-inactivated FBS, 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, and 1% (vol/vol) antibiotic solution (all provided by GIBCO). For experiments in which HSC at different stages of activation were compared, the cells were from the same preparation. All experiments were repeated at least four times with cells obtained from different animals. HSC purity was confirmed by morphological light microscopic appearance, staining of fat droplets with Oil Red O, immunofluorescent staining for ␣-SMA (Sigma), and vitamin A-specific ultraviolet fluorescence. In addition, we performed immunostaining for anti-cytokeratin 18 (Chemicon International) and anti-von Willebrand factor (vWF; Santa Cruz Biotechnologies) to detect the presence of contaminating hepatocytes, bile duct epithelial cells, and endothelial cells. In all of the preparations tested, we never detected endothelial cells, whereas in some preparations we observed Ͻ5% of cytokeratin 18-positive cells.
Histology and Immunostaining
Liver sections (4 m thick) from paraffin-embedded specimens were prepared and stained with hematoxylin/eosin for general histology or with Sirius Red to identify interstitial collagen. A computeraided morphometric analysis was used to quantitatively determine the area of fibrosis. Briefly, a series of digital images was captured from the Sirius Red sections. The areas of fibrosis were measured by using morphometric analysis software (ImageJ). The percentage of the fibrotic area per total liver area was calculated based on each individual animal.
Immunofluorescence staining was performed on liver tissue cryosections and on HSC cultured on sterile cover slips. After fixation with 4% paraformaldehyde and blocking with TBS containing 3% BSA, tissues or cells were probed with a rabbit polyclonal anti-Snail1 antibody (Santa Cruz Biotechnology) (dilution 1:50), a mouse monoclonal anti-␣-SMA Cy3-conjugated antibody (Sigma) (dilution 1:300), a mouse polyclonal anti-glial fibrillary acidic protein (GFAP) antibody (Chemicon International) (dilution 1:50), mouse monoclonal anti-cytokeratin 18 antibody (Chemicon International) (dilution 1:500), or a rabbit anti-vWF antibody (Santa Cruz Biotechnology) (dilution 1:200). After washing, primary antibody was detected with AlexaFluor 488 (Molecular Probes)-conjugated anti-rabbit antibody (dilution 1:200) or donkey anti-mouse fluorescein isothiocyanate-labeled antibody. For nuclear counterstaining, TOTO-3 iodide (Molecular Probes) was used. After washing and mounting, signals were visualized with a Leica TCS-NT/SP2 confocal microscope. Images were digitally stored with Leica software. As a negative control, the primary antibody was replaced with nonimmune IgG. Snail ϩ nuclei were counted in five fields of view at a 20-fold magnification for each condition.
RNA Isolation and RT-PCR Analysis
Total RNA was extracted from liver specimens or HSC with an RNA purification kit (Promega) according to the manufacturers' instructions. RNA (2 g) was reverse transcribed using random hexamers and MuLV reverse transcriptase (Applied Biosystems). Amplification reactions were performed using Power SYBR Green PCR Master Mix (Applied Biosystems). Primer sequences and PCR conditions are reported in Table 1 . Real-time quantitative RT-PCR (qRT-PCR) analysis was performed with the ABI Prism 7700 Sequence Detection System (Applied Biosystems). The expression of all target genes was normalized to glyceraldehyde-3-phosphate dehydrogenase.
RNA Interference
To silence Snail1, specific small-interfering short-hairpin RNA (shRNA) was expressed by adenovirus using the "BLOCK-iT Adenoviral RNAi Expression System" (Invitrogen) according to the manufacturers' protocol. The sequences encoding shRNA for Snail1 (5=-GATG-CACATCCGAAGCCACTTCAAGAGAGTGGCTTCGGATGTG-CATC-3=), previously described by Olmeda et al. (30) , and for LacZ (5=-CTACACAAATCAGCGATTTCGAAAAATCGCTGATTTGT-GTA-3=) were first cloned into pENTR/U6 vector (Invitrogen) and recombinated by a clonase reaction in pAd/BLOCK-iT-DEST (Invitrogen), and adenoviruses AdshSnail1 and AdshLacZ were generated.
HSC were transduced with a multiplicity of infection of 200 the second day of culture and harvested the 8th day of culture for protein or RNA extraction.
For in vivo Snail1 silencing, 10 10 plaque-forming units/kg of AdshSnail1 or AdshLacZ as control were delivered to anesthetized animals by tail-vein injection. After overnight fast (with free access to water), mice were injected intraperitoneally with 1 l/g body wt of sterile CCl 4 in a 1:3 ratio with olive oil. Liver tissue was harvested and snap-frozen for protein and mRNA analysis 3 days later. Blood samples were collected by cardiac puncture in deeply anesthetized animals, centrifuged at 800 g to collect serum, and used to quantify the aspartate transaminase level.
Western Blotting
Liver samples were homogenized in the presence of protease inhibitors (50 mM Tris·HCl, pH 7.6, containing 0.25% Triton X-100, 150 mM NaCl, 10 mM CaCl 2, 0.5 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, 1 M leupeptin, and 150 nM aprotinin). HSC lysates were prepared in a buffer containing 1% Triton X-100, 0.5% wt/vol deoxycholic acid, 10 mM EDTA, 1 M leupeptin, 150 nM aprotinin, and 500 M 4-(2-aminoethyl)benzenesulfonylfluoride in PBS. Particulate material was removed by centrifugation (15,000 g for 30 min at 4°C), supernatants were collected, and protein concentrations were determined using the bicinchoninic acid method (Pierce). Equal amounts of proteins were separated under reducing conditions by using SDS-PAGE. Proteins were electrotransferred onto a polyvinylidene difluoride membrane. The membrane was blocked for 1 h with 5% nonfat dry milk in PBS with 0.05% Tween 20 and immunoblotted in the same buffer with the appropriate antibodies overnight at 4°C [mouse anti-␣-SMA, dilution 1:4,000 (Sigma); goat antiSnail1, dilution 1:500 (Santa Cruz Biotechnology); goat anti-peroxisome proliferator-activated receptor (PPAR)-␥, dilution 1:200 (Santa Cruz Biotechnology); rabbit anti-ILK, dilution 1:1,000 (Cell Signaling), and mouse anti-␤-actin, dilution 1:5,000 (Sigma)]. Membranes were then washed in PBS-Tween 20 and incubated for 1 h at room temperature with secondary horseradish peroxidase-conjugated antimouse IgG (Sigma), anti-rabbit IgG (Sigma), or anti-goat IgG (Santa Cruz Biotechnology) antibody. Specific signals were visualized using the enhanced chemiluminescence detection reagents (Chemicon) and photographed using a VersaDoc imaging system (Bio-Rad).
Human Tissue Samples
The study group included 38 patients aged between 26 to 70 yr (age: 46.0 Ϯ 1.83 yr) who underwent a liver biopsy for diagnostic purposes in the presence of serum markers of hepatitis C virus (HCV) infection. The tissues were immediately frozen in liquid nitrogen and stored at Ϫ80°C until processed for real-time qRT-PCR as described above. Liver fibrosis was semiquantitatively evaluated by the METAVIR scoring system. Fibrosis (F) was staged on a four-point scale according to METAVIR (F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis and few septa; F3, numerous septa without cirrhosis; F4, cirrhosis). All patients were informed about the rationale and possible risks of the study and gave their written informed consent before inclusion. The study protocol has been approved by the Ethics Committee.
Statistical Analysis
Statistical analysis was performed either by Student's t-test, Kruskall-Wallis test, or one-way ANOVA. In cases with more than two groups analyzed, one-way ANOVA was performed with post hoc Bonferroni correction. Pearson correlation coefficient was used to correlate continuous variables. All data are expressed as means Ϯ SE, and P values Ͻ0.05 were considered statistically significant. All data were calculated using the software program SPSS (Software package for the social sciences, Chicago, IL) for Windows, version 15.0.
RESULTS
Snail1 Expression Is Upregulated in Human and Mouse Models of Liver Fibrosis
Snail1 expression was examined in two well-established mouse models of CCl 4 -and TAA-induced liver fibrosis (Fig. 1A ). An increase in Snail1 mRNA (1.40 Ϯ 0.13-fold, P ϭ 0.02 and 1.35 Ϯ 0.12-fold, P ϭ 0.02, respectively) and protein expression was demonstrated in fibrotic livers of CCl 4 -and TAAtreated animals compared with control (Fig. 1B) .
Furthermore, to examine Snail1 mRNA expression during the development of human liver fibrosis, fibrosis stages were arbitrary stratified on the basis of the METAVIR scoring system, as no fibrosis (F0, n ϭ 16), mild fibrosis (F ϭ 1, n ϭ 8 ), significant fibrosis (F ϭ 2, n ϭ 10), or advanced fibrosis (F Ն 3, n ϭ 4). We observed a continuously increasing mRNA expression with disease progression, reaching the highest values in patients with advanced fibrosis (P ϭ 0.001) (Fig. 1C ). Hepatic Snail1 expression was then compared with the expression of type I collagen(␣1) (Col1␣1) using Pearson correlation analysis. We found a significant correlation between Snail1 and Col1␣1 expression (P ϭ 0.01) (Fig. 1D) .
These findings suggest that the development of fibrosis may be associated with Snail1 transcription factor expression.
Snail1 Is Expressed by HSC Following Liver Damage
The HSC is the key fibrogenic cell of the liver and represents a paradigm cell type in studies of the pathogenesis of tissue fibrosis (20 -22) . Snail1 expression has been shown in the cholangiocytes and hepatocytes of fibrotic livers (14, 16), but ␣-SMA, smooth muscle ␣-actin; Col1␣1, type 1 collagen(␣1); Dsp, desmoplakin; Gapdh, glyceraldehyde-3-phosphate dehydrogenase; Mmp, matrix metalloproteinase; Ppar, peroxisome proliferator-activated receptor; bp, base pairs; FW, forward; RV, reverse; TA, annealing temperature. nothing has been reported for HSC. Immunofluorescence analysis revealed the presence of Snail1 in the parenchymal and nonparenchymal cells of CCl 4 -treated mice livers ( Fig. 2A) . Double immunostaining for ␣-SMA and Snail1 showed colocalization of both markers, suggesting that activated myofibroblasts express Snail1. Moreover, we could also observe the presence of Snail1 ϩ ␣-SMA Ϫ and Snail1 Ϫ ␣-SMA ϩ cells. GFAP, a marker of early activation of HSC (8) , was used to better identify nonparenchymal Snail1-expressing cells. As shown in Fig. 2B , Snail1 and GFAP colocalized in CCl 4 -treated mice livers, indicating that the HSC population expresses the transcription factor.
Snail1 Expression Accompanies HSC Transdifferentiation In Vitro
To verify whether in vitro activation of HSC was associated with an increase of Snail1 expression, the mRNA of the transcription factor was quantitated by real-time qRT-PCR analysis in HSC cultured for 1 (quiescent) or 10 (activated) days. As shown in Fig. 3A , there was a significant upregulation of Snail1 transcripts in activated HSC compared with quiescent HSC (1.68 Ϯ 0.13-fold increase, P ϭ 0.006), which was accompanied by increased expression of activation markers such as ␣-SMA and Col1␣1.
Once we ascertained its augmentation in transdifferentiated HSC, we evaluated its distribution in HSC cultured up to 10 days. This analysis evidenced that Snail1 had a cytosolic localization in quiescent HSC (Fig. 3B) ; however, on the 3rd-4th day of culture, we observed its nuclear translocation (in 20 Ϯ 5% of cells, P ϭ 0.05) (Fig. 3C) . On the 10th day of culture, when cells were fully activated, Snail1 was present in the nucleus in discrete foci, with a nonhomogeneous distribution resembling a pattern previously described in some human cancer cell lines (15) (Fig. 3B) . Indeed, we did not observe Snail1 staining in the few cytokeratin-18 positive cells (Ͻ5% of total cells, data not shown).
Characterization of Snail1 Expression in In Vivo Activated HSC
HSC in vitro culture represents the most common model of activation used to study the physiopathological behavior of these cells; however, it doesn't reproduce faithfully the gene expression pattern that occurs in vivo (13) . Indeed, the com- Morphometric analysis was performed on Sirius Red-stained liver sections (n ϭ 4 fields/liver, and 7 livers/group) to measure collagen deposition. *P Ͻ 0.01 vs. control. B: total RNA and proteins were extracted from livers of CCl4-and TAA-treated and control mice. Specific transcripts for the transcription factor Snail1 were quantitated by real-time quantitative RT-PCR (qRT-PCR) analysis. **P Ͻ 0.05 vs. control by Student's t-test. Representative Snail1 and ␤-actin Western blots of whole liver from control and CCl4-and TAA-treated mice are shown. C: total RNA was extracted from liver biopsies of 38 patients affected by chronic liver diseases [no fibrosis (F0), n ϭ 16; mild fibrosis (F1), n ϭ 8; significant fibrosis (F2), n ϭ 10; advanced fibrosis (F Ն 3), n ϭ 4]. The mRNA levels of Snail1 in fibrotic liver in relation to fibrotic staging were assessed by real-time qRT-PCR quantitation. *P Ͻ 0.01 vs. F0 by using one-way ANOVA. D: correlation analysis between human hepatic mRNA levels of Snail1 and type I collagen(␣1) (Col1␣1). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
plex microenvironment of the damaged liver exposes HSC to several cellular and humoral interactions that do not take place in vitro. Thus we decided to further test Snail1 behavior in in vivo activated HSC. HSC were isolated from injured livers of mice treated with a single dose of CCl 4 (in vivo activated HSC) or from healthy livers (quiescent HSC) and then cultured for 20 h. The method used to purify HSC from the hepatic tissue consists of a density gradient that allows isolation of stellate cells based on their buoyancy attributable to intracellular vitamin A. The pool of HSC isolated from injured livers could therefore contain quiescent cells; nevertheless, the activationspecific transcripts ␣-SMA and Col1␣1 resulted in significantly overexpressed HSC isolated from injured livers compared with HSC isolated from control livers (Fig. 4A) . These cells might still retain the vitamin A content to a small extent but are already committed toward an activated phenotype; in other words, they represent transitional HSC that are undergoing transdifferentiation rather than fully activated HSC. Snail1 mRNA resulted upregulated in in vivo activated HSC compared with quiescent HSC (2.55 Ϯ 0.07-fold, P ϭ 0.01) (Fig.   4A ). Moreover, immunofluorescence analysis showed a predominant nuclear localization of Snail1 in in vivo activated HSC (Fig. 4B) . Indeed, also in these experiments, we observed only a minimal presence (Ͻ5% total cells) of cytokeratin-18-positive cells that always resulted Snail1 negative (data not shown). Altogether, these data confirm the overexpression and nuclear distribution of Snail1 during the HSC activation process both in vitro and in vivo.
Snail1 Silencing Inhibits HSC Activation In Vitro
Because Snail1 is implicated in the control of cellular differentiation toward a mesenchymal phenotype, we next investigated whether this transcription factor could regulate the transdifferentiation process of HSC. Mouse HSC isolated and cultured for 36 h were transduced with an adenoviral vector expressing Snail1 small-interfering shRNA (Ad-shSnail1) to silence Snail1 or Ad-shLacZ as control. Cells were harvested the 8th day of culture, when they show a completely activated phenotype. As shown in Fig. 5A , Snail1 mRNA levels were decreased by 72 Ϯ 8% (P ϭ 0.02) in HSC transduced with Ad-shSnail1 compared with control cells, confirming an effective knockdown even 6 days posttransduction. The inhibition of Snail1 expression by small-interfering RNA (siRNA) was accompanied by a dramatic reduction in the activation-related genes ␣-SMA and Col1␣1 mRNA levels (59 Ϯ 5%, P ϭ 0.04; 60 Ϯ 12%, P ϭ 0.007 respectively) and an increase in quiescence-related gene PPAR␥ mRNA levels (244 Ϯ 60%, P ϭ 0.02) (Fig. 5A ). Snail1 knockdown resulted also in the downregulation of the mRNA levels of ILK (48 Ϯ 6%, P ϭ 0.01), a kinase involved in transmission of the ECM signaling that regulates HSC spreading and motility (51), matrix metalloproteinase-9 (52 Ϯ 17%, P ϭ 0.05), a collagenase often associated with tumor cell invasivity (24) and recently implicated in the HSC transdifferentiation process (23) , and the upregulation of desmoplakin (141 Ϯ 14%, P ϭ 0.007), a known Snail1 target gene (29) (Fig. 5A ). Western blot analysis confirmed ␣-SMA and ILK protein suppression and PPAR␥ protein increase after targeted Snail1 siRNA treatment (Fig. 5B) .
Snail1 Silencing Impairs the Hepatic Healing Response In Vivo
We next attempted to elucidate the role of Snail1 in the hepatic wound healing process in vivo. Following acute CCl 4 liver injury, HSC are activated, and their activation peaks at day 3 and then resolves over the next 4 days. Ad-shSnail1 or Ad-shLacZ, as control, were administered 24 h before intraperitoneal CCl 4 injection. Animals were then killed at 72 h post-CCl 4 injection to assess HSC activation. Liver injury was equivalent between the different experimental groups as assessed by histology and serum aspartate transaminase levels (Fig. 6, A and B) . Efficiency of knockdown of Snail1 in vivo was measured by real-time qRT-PCR (Fig. 6C) . Adenoviral shRNA treatment resulted in a drastic decrease in Snail1 expression (P ϭ 0.02) that was associated with a significant reduction in Col1␣1 mRNA expression (Fig. 6C ) (P ϭ 0.01) and ␣-SMA protein levels (Fig. 6D) . Collectively, these results confirm that Snail1 upregulation is a key mechanism in the hepatic healing response.
DISCUSSION
HSC transdifferentiation is part of the normal wound-healing response to liver injury. However, during chronic liver diseases, the mechanisms responsible for tissue healing are persistently activated: the production and deposition of a large amount of extracellular matrix proteins can lead to hepatic disorganization and trigger cirrhosis. Therefore, the understanding of the mechanisms underlying HSC transdifferentiation represents a prerequisite for the potential identification of dysfunctional signaling pathways and the development of specific therapies.
In this work, we characterized the transcription factor Snail1 in the context of the hepatic healing response, and we evaluated its role in the activation process of HSC. In particular, we showed that: 1) in human liver fibrosis as well as in two different experimental models of liver injury, Snail1 expression is increased significantly; 2) Snail1 expression is related to the transdifferentiation of HSC to an activated phenotype both in vitro and in vivo; and 3) in vitro and in vivo Snail1 silencing impedes the HSC activation and damps down the hepatic wound-healing response. Fig. 6 . In vivo Snail1 knockdown attenuates the hepatic healing response. Ad-shSnail1 or Ad-shLacZ as control were delivered to anesthetized animals by tail-vein injection (n ϭ 5 mice in each group). After 24 h, mice were injected ip with CCl4, and, after 3 days, animals were killed and tissue harvested for: hematoxylin/eosin staining of liver sections (A), serum aspartate transaminase (AST) levels (B), and real-time qRT-PCR quantitation of Snail1, Col1␣1, and ␣-SMA expression in liver homogenates (C). **P Ͻ 0.05 vs. Ad-shLacZ. D: ␣-SMA and ␤-actin Western blots of whole liver protein extract.
The concept of Snail1 as master regulator of EMT during embryonic development and cancer progression is well established but somehow restrictive. Analyzing the cellular properties conferred by this transcription factor, several lines of evidence point to a role for Snail1 as a regulator of cellular motility and adhesion. It is essential to generate organs and tissues far from the original location in the embryo and promote cell delamination from primary tumor and metastasis formation in the adult (6) . It can be expressed not only by epithelial cells but also by terminal differentiated mesenchymal cells, which reactivate its expression to drive three-dimensional invasion programs (36) .
In the context of wound healing, Snail1 may contribute to the activation and migration of myofibroblasts to the injured site, a fundamental step for the reconstitution and the remodeling of the ECM. Indeed, a recent study showed that Snail1 governs multiple processes critical to fibroblast motile behavior, including adhesion, migration, and proteolysis (36) . Furthermore, an in vivo wound-healing assay evidenced that Snail1 is expressed only by activated migrating fibroblasts, and fibroblasts result in Snail1 ϩ fibromatosis, a pathological condition characterized by the proliferation of activated fibroblasts with a high invasivity potential (19) .
In this study, we showed that HSC, one of the main sources of myofibroblast in the liver, are Snail1 ϩ . The expression of this transcription factor is significantly upregulated at the mRNA level in HSC activated both in vitro and in vivo, whereas at the protein level it has a nuclear localization in activated and transdifferentiating cells. This underlines the importance of Snail1 posttranslational regulation, which controls the intracellular location of the transcription factor by means of phosphorylation by several enzymes such as glycogen synthase kinase 3␤ (GSK-3␤) (52), p21-activated kinase-1 (48), and LIV-1 (46) , all of which to our knowledge have not been characterized in HSC yet. Furthermore, a recent work proved that lysyl oxidase-like2 and 3 (LOXL2/3), enzymes involved in connective tissue biogenesis, stabilize Snail1 nuclear localization by modification of lysines K98 and K137 (34) . Interestingly, both LOXL2 and LOXL3 have been detected in the fibrotic septa of human samples of HCV-and HBV-related chronic hepatitis (44) , suggesting their potential role in Snail1 regulation in hepatic fibrogenesis.
Our Snail1 knockdown experiments confirmed its role in promoting the activation process in HSC. Snail1 suppression was associated with a diminished expression of two classical HSC activation marker genes, ␣-SMA and type I procollagen.
Snail1 binds to E-box consensus sequences on the promoters of its target genes, where it has been shown to act as a transcriptional repressor. Without a chromatin immunoprecipitation analysis, we cannot affirm that Snail1 is directly responsible for the transcriptional induction of profibrogenic genes such as ␣-SMA and Col1a1; indeed, it is possible that it affects it indirectly by repressing other antifibrotic/anti-inflammatory genes, transcription factors, or chromatin-modifying enzymes. For instance, it has been shown that Snail1 represses and associates to the promoter of phosphatase and tensin homolog deleted from the chromosome 10 gene, a negative effector of the PI 3-kinase pathway (17) recently shown to represent an important negative regulator for the transactivation of HSC (41) . Moreover, we speculate that PPAR␥, whose repression is crucial for enabling the transdifferentiation of quiescent HSC to myofibroblasts, may be a potential target of Snail1 since its promoters contains six E-box elements (18) , and, in our assay, its expression was significantly increased by Snail1 silencing. It is becoming increasingly clear that the reprogramming of HSC transcriptome to that of a myofibroblast involves epigenetic mechanisms (28) . Interestingly, recent works have pointed out how Snail1's transcriptional repressor functions are connected with the epigenetic regulation of gene expression. Snail1 can recruit several chromatin-modifying enzymes, such as histone methyltransferases, demethylases, and deacetylases, leading to transcriptional repression in a multistage process (11) . Altogether, these histone modifications lead to an initial epigenetic silencing of gene promoters that can be lately converted into a long-term repression by DNA hypermethylation with a mechanism still unresolved.
Snail1 silencing damps down the hepatic healing response in vivo. Because adenoviral delivery of sh-Snail1 is not restricted to HSC but can also target parenchymal cells, we cannot state that the effect observed is solely due to attenuated Snail1 signaling in HSC alone. Other mechanisms may be involved in the Snail1-mediated hepatic healing response. Snail1 silencing could impede the EMT of hepatocytes and cholangiocytes, although the occurrence of EMT in liver fibrosis has recently been questioned (38, 42) . Alternatively, a hepatocyte-mediated effect can be possible. Snail1 expression has shown an inverse correlation with expression of hepatocyte nuclear factors (HNF) and can both control epithelial polarity and influence the liver-specific gene expression through binding to the Eboxes present in the HNF4␣ promoter (9, 49) . Besides, it has been shown to participate in TGF-␤ signaling leading to Col1a1 expression in hepatocytes (16) . Thus, Snail1 silencing may reduce the hepatic healing response by preserving the functional differentiation of hepatocytes and blunting profibrogenic TGF-␤ signaling.
In the CCl 4 and TAA hepatic fibrosis models, the level of Snail1 mRNA was significantly upregulated compared with controls. Its transcriptional induction could be due to several factors known for their involvement in the progression of hepatic fibrogenesis such as TGF-␤, reactive oxygen species, and NF-B (43) . Consistent with our findings in the animal models, the data obtained from the analysis of human chronic hepatitis specimens support an increasing Snail1 mRNA expression with disease progression and evidence its correlation with type I procollagen mRNA level. Based on these data, the main cell source of Snail1 in the human fibrotic liver cannot be established, although a multiple cell-type origin is suggested by other studies.
Indeed, immunostaining of fibrotic livers from mice treated with CCl 4 revealed the presence of Snail1 ϩ ␣-SMA ϩ cells, as well as Snail1 ϩ ␣-SMA Ϫ and Snail1 Ϫ ␣-SMA ϩ cells along the fibrotic septa. This staining pattern could be explained by the heterogeneity of the HSC population, as demonstrated by Magness et al. (27) , who described the existence of different HSC subpopulations based on their expression of ␣-SMA and/or collagen type I in ␣-SMA-RFP/Col1a1-EGFP doubletransgenic mice. Still we cannot exclude that Snail1 ϩ ␣-SMA Ϫ cells are not stellate cells but parenchymal cells undergoing EMT. Indeed, several recent studies pointed out that this process contributes to hepatic fibrosis development, but the issue still remains controversial (10) . Some works have previously reported the transdifferentiation in vitro from hepato-cytes to mesenchymal cells (32, 40, 50) , but whether the process occurs in vivo has recently been argued (42) . The EMT of the biliary tree cells has also been shown (31) , and evidence of the process has been observed in human primary biliary cirrhosis (35) and in the fibrosis associated with biliary atresia (14) . Dooley et al. (16) reported that liver sections from mice with CCl4-induced fibrosis displayed nuclear Snail1 staining in hepatocytes located around injured areas. Their observation was confirmed in human tissues, where Snail1 was present at the border of inflamed regions with significant scar formation. Notably, they also observed Snail1 ϩ cells lacking transferrin, a hepatic marker, and hypothesize that these cells are hepatocytes in a later stage of transition or originating from an infiltrating cell. Indeed, it is not possible to rule out that these cells are HSC instead. Our data provide a further analysis of the hepatic cell populations expressing Snail1 in the injured liver, putting forward the notion that Snail1 transcription factor is involved also in HSC activation.
Then again, we cannot rule out that HSC themselves undergo an EMT process. Previous reports showed the simultaneous expression of epithelial and mesenchymal markers by HSC (26) and hepatic progenitor cells in vitro and in a murine model of hepatic fibrosis (39) . In addition, it recently emerged that a subpopulation of HSC express pluripotent stem cell markers potentially able to give rise to hepatocytes and endothelial cells (25) . In this extremely dynamic scenario pointing out the plasticity of the HSC phenotype, Snail1 may have a role in the commitment of quiescent HSC toward an activated mesenchymal phenotype.
Overall, our work supports a role for Snail1 transcription factor in liver repair and HSC activation, offering a basis for further studies aimed to the development of therapeutic strategies to treat specifically hepatic fibrosis.
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